Showing 4311-4320 of 6036 results for "".
- Bausch + Lomb Launches New Range of Pure‐Line Gases at Euretinahttps://modernod.com/news/bausch-lomb-launches-new-range-of-pureline-gases-at-euretina-1/2481869/Bausch + Lomb announced the European launch of the new range of Pure‐line gases during the European Society of Retina Specialists (Euretina) annual meeting, taking place in Amsterdam, The Netherlands, Oct. 5‐ 8, 2023. Designed for ease of use, the Pure‐line gases are available as both p
- Resolving a Seeming Contradiction, Study Advances Understanding of Visual Recognition Memoryhttps://modernod.com/news/resolving-a-seeming-contradiction-study-advances-understanding-of-visual-recognition-memory/2481866/Researchers from The Picower Institute for Learning and Memory have published a study evaluating how our vision is so good at recognizing what’s familiar. The study, published in the Journa
- Humonix Biosciences Launches 3D Human Tissue Modelhttps://modernod.com/news/specialty-pharmaceutical-research-company-humonix-biosciences-launches-3d-human-tissue-model/2481864/Humonix Biosciences has developed a new 3D human tissue model called the retinal vascular dysfunction model. Humonix’s new model is a physiologically relevant 3D model of the blood-retinal barrier. This model expresses key physiological and biological characteristics, providing a platf
- Bausch + Lomb Completes Acquisition of Xiidrahttps://modernod.com/news/bausch-lomb-completes-acquisition-of-xiidra/2481861/Bausch + Lomb announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution 5%), a non-steroid eye drop approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. In June, Bausch + Lomb&
- Neurolens Introduces N3 VR-Based Measurement and Education Experiencehttps://modernod.com/news/neurolens-introduces-n3-vr-based-measurement-and-education-experience/2481854/Neurolens has introduced N3—a virtual reality experience designed to educate patients while measuring eye alignment. N3 provides an objective, accurate, and repeatable measurement of binocular alignment, which incorporates elements of heterophoria, fixation disparit
- Thea Pharma Announces the US Launch of Glaucoma Drug Iyuzehhttps://modernod.com/news/thea-pharma-announces-the-us-launch-of-glaucoma-drug-iyuzeh/2481850/Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (
- PPG, Flō-Optics Announce Supplier Agreement for Digitally Applied Optical Coatingshttps://modernod.com/news/ppg-flo-optics-announce-supplier-agreement-for-digitally-applied-optical-coatings/2481849/PPG announced an exclusive supplier agreement with Flō-Optics, a developer of digital manufacturing technology for the ophthalmic industry, for the application of PPG HI-GARD scratch-resistant coatings using Flō’s proprietary digital printing technology. Financial terms of th
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf
- Bausch + Lomb Launches Lumify Eye Illuminations in the UShttps://modernod.com/news/bausch-lomb-launches-lumify-eye-illuminations-in-the-united-states/2481846/Bausch + Lomb announced the US launch of Lumify Eye Illuminations, a new line of hypoallergenic specialty eye care products developed to cleanse, nourish and brighten the sensitive eye area. “Many products contain chemicals or preservatives that can irritate the del
- OcuCell Announces Funding from the Georgia Eye Bankhttps://modernod.com/news/ocucell-announces-funding-from-the-georgia-eye-bank/2481845/OcuCell, a provider of ocular cell therapy, announce funding from the Georgia Eye Bank. Founded in 1961, Georgia Eye Bank has provided over 60,000 corneas for transplant and is dedicated to improving vision and lives through transplantation of ocular tissue and cells. Fin